
Cellibre, Inc. has raised $6.7M in total funding. The most recent round was Series A.
Cellibre, Inc. is headquartered in San Diego, CA.
Traditional, farm- and smokestack-based manufacturing of products is not sustainable for the planet.
Cellibre uses synthetic biology -- strain engineering, biochemistry, and precision fermentation -- to design microbes that manufacture products, shifting production 'from the farm to fermentation.'
The page points to an integrated 'Bootup Biology' approach spanning strain engineering, protein/biochemistry optimization, and precision fermentation, and cites industry validation including an investment from Symrise and recognition as a winner of Ajinomoto's Next Generation of Taste and Texture Technologies (NGT3) competition.
Cellibre, a San Diego biotech founded by CEO Ben Chiarelli in 2019, closed an $11.5M Series A led by Merida Capital Holdings to commercialize lab-cultured (fermentation-based) cannabinoids.
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.